SomaLogic and NEC announce launch of SomaSuite™

5/17/2012

 

Professional software tool provides simple, reliable and direct access to SOMAscan™ data

Boulder, CO, USA and Tokyo, Japan – May 17, 2012

SomaLogic, Inc., and NEC Corporation (NEC; TSE: 6701) today announced the release of SomaSuite, a professional software tool developed by NEC that provides simple, reliable and direct access to the highly multiplexed proteomic data generated by SomaLogic’s SOMAscan assay technology. SomaSuite Version 1.0 enables all clinical researchers, regardless of their level of bioinformatic expertise, to analyze the hundreds of measurements over thousands of proteins produced by the SOMAscan assay. SomaSuite provides an intuitive graphic display that enables researchers to quickly discover significant protein expression changes in their biological samples.

Since their first agreement in 2010, SomaLogic and NEC have worked to establish a long-term strategic relationship between the companies to integrate NEC’s information technology as an enhancement of SomaLogic’s products for life sciences research, drug discovery and development, and diagnostics. SomaSuite is the first product developed under this agreement, and it is now included as a part of the SOMAscan assay service.

SomaSuite is a stand-alone, Windows-based software tool designed for simplicity and usability. It features a workflow-driven interface that guides the user from raw data to results, including:

  • Rapid grouping (and re-grouping) of samples for easy user-generated comparisons;
  • Tests to identify difference in protein response (or differential protein regulation) between groups of samples;
  • Visualization of results in a variety of formats;
  • Selection of proteins of interest identified during the analysis steps.

“Our strategic partnership with NEC is a critical element of our own efforts to unlock protein biomarker discovery for our many collaborators in biopharmaceuticals and academia,” said Larry Gold, Ph.D., CEO and Chairman of the Board of SomaLogic. “The release of SomaSuite draws on NEC’s expertise in developing software that creates value from complex datasets, and makes our SOMAscan technology accessible to everyone interested in protein biomarker discovery.”

“We undertook this collaboration with SomaLogic to leverage the unique strengths of both companies for the purpose of optimizing the use of protein biomarkers to provide better healthcare, and thus to enhance people’s lives worldwide,” said Takuya Yamaguchi, General Manager of NEC’s Medical Solutions Division. “Providing quick and direct access to results from the powerful protein biomarker platform is an important step towards realizing that shared goal.”

_________

About SomaLogic
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company’s mission is to use its proprietary proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. By providing a combination of products and solutions that cross utilize the company’s experience and global resources, NEC’s advanced technologies meet the complex and ever-changing needs of its customers. NEC brings more than 100 years of expertise in technological innovation to empower people, businesses and society. For more information, visit NEC at http://www.nec.com.

About SOMAscan™/SOMAmers™
SomaLogic’s proprietary SOMAscan™ proteomic technology platform underlies a rapidly growing number of new diagnostic and therapeutic opportunities. The power of the SOMAscan platform comes from its use of a new generation of nucleic acid-based protein-binding reagents, called SOMAmers™ (Slow Off-rate Modified Aptamers). The unique physical properties of SOMAmers empower the accurate detection and measurement of thousands of proteins over a wide range of concentrations in just a few drops of blood (or other tissues), all in a single SOMAscan assay.

For further information please contact:

SomaLogic:
Fintan R. Steele, Ph.D.
Executive Director of Communications
Email: fsteele@somalogic.com
Phone: +1 720-214-3080

NEC:
Takehiko Kato
NEC Corporation
t-kato@cj.jp.nec.com
+81-3-3798-6511